Dual carbonic anhydrase -: Cyclooxygenase-2 inhibitors

被引:37
作者
Dogne, Jean-Michel
Thiry, Anne
Pratico, Domenico
Masereel, Bernard
Supuran, Claudiu T.
机构
[1] Univ Namur, Drug Design & Discovery Ctr Fdn, Dept Pharm, B-5000 Namur, Belgium
[2] Univ Penn, Sch Med, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA
[3] Univ Florence, Lab Chim Bioinorgan, I-50019 Sesto Fiorentino, Italy
关键词
D O I
10.2174/156802607780636717
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cyclooxygenase is a key enzyme responsible for metabolisation of arachidonic acid into prostaglandins and thromboxane. This enzyme is the target of non steroidal anti-inflammatory drugs (NSAIDs), used against inflammation and pain. The inducible COX-2 was associated with inflammatory conditions, whereas the constitutive form (COX-1) was responsible for the beneficial effects of the PGs. This observation led to the development of COX-2 inhibitors or "coxibs" of which rofecoxib (Vioxx (R)) characterized by a methylsulfone moiety and the sulfonamides celecoxib (Celebrex (R)) and valdecoxib (Bextra (R)). Initially described as COX-2 "selective" inhibitors, recent reports revealed a nanomolar inhibition activity of the sulfonamide COX-2 inhibitors for several carbonic anhydrase (CA) isoforms, confirmed by X-ray crystal structures for the adducts of celecoxib and valdecoxib with isozyme CA II. This dual activity may help to explain differences in clinical observation between sulfonamide and methylsulfone COX-2 inhibitors. Moreover, the inhibition of CA isozymes, critical for the development and invasion of cancer cells, such as CA II, IX and XII, may constitute an important mechanism of antitumor action of such sulfonamide compounds.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 50 条
[1]   Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors [J].
Abbate, F ;
Casini, A ;
Scozzafava, A ;
Supuran, CT .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2003, 18 (04) :303-308
[2]   Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: Role of hydrogen-bonding networks in ligand binding and drug design [J].
Abbate, F ;
Supuran, CT ;
Scozzafava, A ;
Orioli, P ;
Stubbs, MT ;
Klebe, G .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (17) :3583-3587
[3]   Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2 [J].
Bartosová, M ;
Parkkila, S ;
Pohlodek, K ;
Karttunen, TJ ;
Galbavy, S ;
Mucha, V ;
Harris, AL ;
Pastorek, J ;
Pastoreková, S .
JOURNAL OF PATHOLOGY, 2002, 197 (03) :314-321
[4]   COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression [J].
Chandrasekharan, NV ;
Dai, H ;
Roos, KLT ;
Evanson, NK ;
Tomsik, J ;
Elton, TS ;
Simmons, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13926-13931
[5]   Role of prostacyclin in the cardiovascular response to thromboxane A2 [J].
Cheng, Y ;
Austin, SC ;
Rocca, B ;
Koller, BH ;
Coffman, TM ;
Grosser, T ;
Lawson, JA ;
FitzGerald, GA .
SCIENCE, 2002, 296 (5567) :539-541
[6]  
de Leval X, 2000, CURR MED CHEM, V7, P1041
[7]  
de Leval X, 2004, MINI-REV MED CHEM, V4, P597
[8]   Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib [J].
Di Fiore, A ;
Pedone, C ;
D'Ambrosio, K ;
Scozzafava, A ;
De Simone, G ;
Supuran, CT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (02) :437-442
[9]   Adverse cardiovascular effects of the coxibs [J].
Dogné, JM ;
Supuran, CT ;
Pratico, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2251-2257
[10]   Coxibs and cardiovascular side-effects:: From light to shadow [J].
Dogné, JM ;
Hanson, J ;
Supuran, C ;
Pratico, D .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (08) :971-975